Please assess the completion status of the following clinical trial:

Trial Title: Lamazym Aftercare Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* the subject must have participated in previous Lamazym-trials: phase 2b: 2011-004355-40 or phase 3: 2012-000979-17~* Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities~* The subject and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~* Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial~* Any other medical condition or serious intercurrent illness, or extenuating circumstances that, in the opinion of the Investigator, would preclude participation in the trial~* Pregnancy. Pregnant woman is excluded. Before start fot he treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception~* Psychosis; any psychotic disease, also in remission, is an exclusion criteria~* Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamazym (Type: EXPERIMENTAL): 1 mg Lamazym/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).